[EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
申请人:REGENERON PHARMA
公开号:WO2021003295A1
公开(公告)日:2021-01-07
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
本公开涉及能够调节羟基类固醇17-β脱氢酶(HSD17B)家族成员蛋白的化合物和药物组合物,包括抑制HSD17B家族成员蛋白,例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法,其中HSD17B家族成员蛋白发挥作用。